Revolution Medicines Shares Rise 54% Following Positive Pancreatic Cancer Drug Trial Results
Revolution Medicines (RVMD) shares surged 54.13% following positive results from its late-stage clinical trial for its pancreatic cancer treatment, Daraxonrasib. The drug showed a median overall survival of 13.2 months, compared to 6.7 months with chemotherapy alone. Analysts have upgraded their ratings and raised price targets, signaling strong market optimism.
Tickers: $RVMD
Topics: analyst recommendations clinical trial results FDA approval pharmaceuticals stock price movement